Capmatinib is the first MET inhibitor that has gained recent Food and Drug Administration approval for the treatment of advanced NSCLC with MET∆ex14 [18], and novel mechanisms of resistance have meanwhile started to emerge [19]. The gene discussed is MET; the disease is non-small cell lung carcinoma.